Penumbra/$PEN
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Ticker
$PEN
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
4,500
ISIN
US70975L1070
Website
Penumbra Metrics
BasicAdvanced
$9.8B
235.23
$1.08
0.53
-
Price and volume
Market cap
$9.8B
Beta
0.53
52-week high
$310.00
52-week low
$148.00
Average daily volume
523K
Financial strength
Current ratio
6.302
Quick ratio
3.447
Long term debt to equity
16.972
Total debt to equity
18.193
Interest coverage (TTM)
110.49%
Profitability
EBITDA (TTM)
167.533
Gross margin (TTM)
66.37%
Net profit margin (TTM)
3.41%
Operating margin (TTM)
11.92%
Effective tax rate (TTM)
15.70%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
5.82%
Return on equity (TTM)
3.50%
Valuation
Price to earnings (TTM)
235.227
Price to revenue (TTM)
7.892
Price to book
8.09
Price to tangible book (TTM)
9.43
Price to free cash flow (TTM)
65.102
Free cash flow yield (TTM)
1.54%
Free cash flow per share (TTM)
389.51%
Growth
Revenue change (TTM)
13.17%
Earnings per share change (TTM)
-54.65%
3-year revenue growth (CAGR)
16.60%
10-year revenue growth (CAGR)
24.53%
3-year earnings per share growth (CAGR)
81.99%
10-year earnings per share growth (CAGR)
23.65%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Bulls say / Bears say
Penumbra's U.S. thrombectomy revenue increased by 25% year-over-year to $187.9 million, with the U.S. VTE franchise achieving a remarkable 42% growth, highlighting the company's leadership in this sector. (TipRanks)
The company achieved a gross margin of 66.6%, representing a 160 basis point increase over the prior year period, reflecting operational efficiency and effective cost management. (TipRanks)
Penumbra received FDA clearance for Ruby XL, a new larger size diagnostic catheter-compatible peripheral coil, with plans for a market launch in late Q2 or early Q3, potentially boosting future revenue streams. (TipRanks)
Penumbra reported a loss from operations of $81.0 million in Q2 2024, primarily due to $110.3 million in one-time non-cash impairment and inventory write-down charges related to its Immersive Healthcare assets. (GuruFocus)
The company faced a decline in international revenue, which decreased by 9.4% adjusted, primarily due to reduced sales in China, highlighting challenges in global market expansion. (GuruFocus)
Penumbra updated its full-year 2024 revenue guidance to a range of $1,180 million to $1,200 million, down from the previous range of $1,230 million to $1,270 million, citing challenges such as a difficult economic backdrop in China and delays in product launches in Europe. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Penumbra News
AllArticlesVideos
3 Mid-Cap Medical Stocks Outperforming the Market
MarketBeat·2 months ago
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
Benzinga·2 months ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $9.8B as of June 27, 2025.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 235.23 as of June 27, 2025.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.